Nymox Pharmaceutical Corporation(NYMXF.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Nymox Pharmaceutical Corporation
NYMXF.US
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer’s disease.
1.951 T
NYMXF.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Daniel J. Anderson, Ph.D. appointed Chief Scientific Officer of Integrated Biosciences in Redwood City, California.

    Integrated Biosciences, a California-based biotechnology firm, has appointed Dr. Daniel J. Anderson, Ph.D., as their new Chief Scientific Officer. Dr. Anderson will be in charge of overseeing the company's scientific strategy and pipeline development in the discovery of small-molecule therapeutics for age-related diseases. Prior to joining Integrated Biosciences, Dr. Anderson was associated with Eikon Thera. Dr. Anderson's appointment aims to strengthen the company's proprietary platform for research in synthetic biology, chemistry, and AI.

    Unusual Whales·
    Unusual Whales·

    "Hong Kong Stocks" Hang Seng Index opened high, up 97 points, Anta rises, Zijin up 4%

    The Hong Kong stock market opened higher in the morning, with the Hang Seng Index rising 97 points to 26,863 points, and the National Index and Hang Seng Tech Index opening up 25 points and 8 points respectively. Alibaba opened up 1%, Sunny Optical opened up 0.2%. Anta acquired a stake in Puma, with its stock opening up 1.5%. Zijin Gold International fully acquired United Gold, with its stock opening up 3%. Other tech stocks showed mixed performance, with Tencent opening up 0.1% and JD.com opening down 0.2%

    AASTOCKS·
    HK
    09988
    +2.85%
    HK
    02899
    +2.89%
    SH
    601899
    +2.81%
    AASTOCKS·
    HK
    09988
    +2.85%
    HK
    02899
    +2.89%
    SH
    601899
    +2.81%

    American Academy of Pediatrics departs from CDC with childhood vaccine revisions

    The American Academy of Pediatrics (AAP) has published its own childhood immunization schedule for 2026, diverging from the CDC's recent guidance. The AAP recommends vaccinations against diseases the CDC has dropped, including hepatitis A and B, meningococcal disease, rotavirus, flu, and RSV. AAP President Andrew Racine criticized the CDC's decision as "dangerous and unnecessary," expressing concerns about public confusion. The AAP is also involved in legal actions against the Trump administration regarding immunization policies and funding cuts.

    Thehill·
    Thehill·

    Deals of the day-Mergers and acquisitions

    On January 26, various mergers and acquisitions were reported, including Eaton Corp's spin-off of its automotive businesses, The Platform Group's acquisition of AEP Pharma Group, and Century Aluminum's stake in Emirates Global Aluminium. IonQ plans to buy SkyWater Technology for $1.8 billion, while XRG is increasing its stake in Rio Grande LNG. MOL is acquiring a majority stake in Serbia's NIS for up to $1.19 billion. Zijin Gold will buy Allied Gold for C$5.5 billion, and Leidos Holdings is acquiring ENTRUST Solutions for $2.4 billion. CVC is buying Marathon for up to $1.2 billion, and Spire Healthcare shares surged amid buyout talks. EFG International will acquire Quilvest Switzerland, and EP Group plans to take control of Fnac Darty, boosting its shares by 18%. Merck is no longer pursuing Revolution Medicines.

    Reuters·
    US
    VIS
    -0.04%
    US
    SKYT
    +3.29%
    US
    LDOS
    -0.90%
    Reuters·
    US
    VIS
    -0.04%
    US
    SKYT
    +3.29%
    US
    LDOS
    -0.90%

    NanoFuse outperforms DBM and bioactive glass, validated by a study in the Int. Journal of Spine Surgery. Significant implications for spinal fusion.

    A recent study published in the International Journal of Spine Surgery has provided robust scientific support for NanoFuse as an advanced synthetic biologic for bone regeneration, particularly in the context of spinal fusion. This research, based in Fort Lauderdale, Florida and conducted on (specific number) patients, underscores the promising potential of NanoFuse in enhancing bone healing processes. The findings highlight the efficacy of NanoFuse and suggest its possible future significance in spinal fusion procedures.

    Unusual Whales·
    Unusual Whales·
    © 2026 Longbridge｜Disclaimer